147 related articles for article (PubMed ID: 11392461)
1. Inhibition of T-type and L-type calcium channels by mibefradil: physiologic and pharmacologic bases of cardiovascular effects.
Leuranguer V; Mangoni ME; Nargeot J; Richard S
J Cardiovasc Pharmacol; 2001 Jun; 37(6):649-61. PubMed ID: 11392461
[TBL] [Abstract][Full Text] [Related]
2. Role of membrane depolarization and T-type Ca2+ channels in angiotensin II and K+ stimulated aldosterone secretion.
Lotshaw DP
Mol Cell Endocrinol; 2001 Apr; 175(1-2):157-71. PubMed ID: 11325526
[TBL] [Abstract][Full Text] [Related]
3. Differential interactions of Na+ channel toxins with T-type Ca2+ channels.
Sun H; Varela D; Chartier D; Ruben PC; Nattel S; Zamponi GW; Leblanc N
J Gen Physiol; 2008 Jul; 132(1):101-13. PubMed ID: 18591418
[TBL] [Abstract][Full Text] [Related]
4. Effect of mibefradil on sodium and calcium currents.
Strege PR; Bernard CE; Ou Y; Gibbons SJ; Farrugia G
Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G249-53. PubMed ID: 15790762
[TBL] [Abstract][Full Text] [Related]
5. Mibefradil, an I(Ca,T) blocker, effectively blocks I(Ca,L) in rabbit sinus node cells.
Protas L; Robinson RB
Eur J Pharmacol; 2000 Jul; 401(1):27-30. PubMed ID: 10915833
[TBL] [Abstract][Full Text] [Related]
6. State-dependent inhibition of inactivation-deficient Ca(V)1.2 and Ca(V)2.3 channels by mibefradil.
Bernatchez G; Sauvé R; Parent L
J Membr Biol; 2001 Nov; 184(2):143-59. PubMed ID: 11719851
[TBL] [Abstract][Full Text] [Related]
7. Lercanidipine and T-type calcium current.
Cerbai E; Mugelli A
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(12):4025-4031. PubMed ID: 29949180
[TBL] [Abstract][Full Text] [Related]
8. Voltage-dependent Ca2+ currents contribute to spontaneous Ca2+ waves in rabbit corpus cavernosum myocytes.
McCloskey C; Cagney V; Large R; Hollywood M; Sergeant G; McHale N; Thornbury K
J Sex Med; 2009 Nov; 6(11):3019-31. PubMed ID: 19694931
[TBL] [Abstract][Full Text] [Related]
9. Effects of mibefradil, a selective T-type Ca2+ channel antagonist, on sino-atrial node and ventricular myocardia.
Masumiya H; Kase J; Tanaka Y; Tanaka H; Shigenobu K
Res Commun Mol Pathol Pharmacol; 1999; 104(3):321-9. PubMed ID: 10741382
[TBL] [Abstract][Full Text] [Related]
10. Mibefradil (Ro 40-5967) blocks multiple types of voltage-gated calcium channels in cultured rat spinal motoneurones.
Viana F; Van den Bosch L; Missiaen L; Vandenberghe W; Droogmans G; Nilius B; Robberecht W
Cell Calcium; 1997 Oct; 22(4):299-311. PubMed ID: 9481480
[TBL] [Abstract][Full Text] [Related]
11. Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967).
Bezprozvanny I; Tsien RW
Mol Pharmacol; 1995 Sep; 48(3):540-9. PubMed ID: 7565636
[TBL] [Abstract][Full Text] [Related]
12. Effect of mibefradil on voltage-dependent gating and kinetics of T-type Ca(2+) channels in cortisol-secreting cells.
Gomora JC; Xu L; Enyeart JA; Enyeart JJ
J Pharmacol Exp Ther; 2000 Jan; 292(1):96-103. PubMed ID: 10604935
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2.
Moosmang S; Haider N; Brüderl B; Welling A; Hofmann F
Circ Res; 2006 Jan; 98(1):105-10. PubMed ID: 16306443
[TBL] [Abstract][Full Text] [Related]
14. Selectivity of different calcium antagonists on T- and L-type calcium currents in guinea-pig ventricular myocytes.
De Paoli P; Cerbai E; Koidl B; Kirchengast M; Sartiani L; Mugelli A
Pharmacol Res; 2002 Dec; 46(6):491-7. PubMed ID: 12457621
[TBL] [Abstract][Full Text] [Related]
15. Identification of T-type alpha1H Ca2+ channels (Ca(v)3.2) in major pelvic ganglion neurons.
Lee JH; Kim EG; Park BG; Kim KH; Cha SK; Kong ID; Lee JW; Jeong SW
J Neurophysiol; 2002 Jun; 87(6):2844-50. PubMed ID: 12037187
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of voltage- and use-dependent block of class A Ca2+ channels by mibefradil.
Aczél S; Kurka B; Hering S
Br J Pharmacol; 1998 Oct; 125(3):447-54. PubMed ID: 9806326
[TBL] [Abstract][Full Text] [Related]
17. T-type CaV3.3 calcium channels produce spontaneous low-threshold action potentials and intracellular calcium oscillations.
Chevalier M; Lory P; Mironneau C; Macrez N; Quignard JF
Eur J Neurosci; 2006 May; 23(9):2321-9. PubMed ID: 16706840
[TBL] [Abstract][Full Text] [Related]
18. NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels.
Huang L; Keyser BM; Tagmose TM; Hansen JB; Taylor JT; Zhuang H; Zhang M; Ragsdale DS; Li M
J Pharmacol Exp Ther; 2004 Apr; 309(1):193-9. PubMed ID: 14718587
[TBL] [Abstract][Full Text] [Related]
19. Involvement of T-type calcium channels in excitatory junction potentials in rat resistance mesenteric arteries.
Xi Q; Ziogas J; Roberts JA; Evans RJ; Angus JA
Br J Pharmacol; 2002 Nov; 137(6):805-12. PubMed ID: 12411411
[TBL] [Abstract][Full Text] [Related]
20. Single-channel pharmacology of mibefradil in human native T-type and recombinant Ca(v)3.2 calcium channels.
Michels G; Matthes J; Handrock R; Kuchinke U; Groner F; Cribbs LL; Pereverzev A; Schneider T; Perez-Reyes E; Herzig S
Mol Pharmacol; 2002 Mar; 61(3):682-94. PubMed ID: 11854450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
